Objective. The aim of this study was to investigate whether a core of echocardiography-based definitions of pulmonary hypertension (PH), as proposed by the European Society of Cardiology, European Respiratory Society and International Society of Heart and Lung Transplantation (ESC/ERS/ISHLT), may predict long-term survival in patients with SLE.
Introduction
Pulmonary hypertension (PH) is a non-specific pathophysiological condition defined as any increase in the mean pulmonary artery (PA) pressure 525 mmHg at rest, assessed by right heart catheterization. According to various combinations of haemodynamic parameters and aetiologies, PH is classified into five groups: precapillary PH, which includes pulmonary arterial hypertension (PAH) and veno-occlusive disease (group 1); PH due to lung diseases (group 3); chronic pulmonary thromboembolism (group 4); PH with unclear or multifactorial mechanisms (group 5) and post-capillary PH, which includes those cases due to left heart disease (group 2) [1, 2] .
PAH is a well-recognized complication of several autoimmune disorders, including SSc, SS and SLE [3] . In the latter, PH may also be secondary to pulmonary thromboembolism or cardiopulmonary complications, and all groups of PH can be found [4] . Although PH is not a new complication of SLE, many features and associations are not well characterized [58] . For instance, the prevalence of PH has been estimated to be as low as 0.5% (measured by catheterization and defined as a mean PA pressure >40 mmHg) or as high as 14% (PA systolic pressure >30 mmHg by echocardiography) in patients with SLE [9, 10] . Similarly, the impact of PH on the survival of patients with SLE varies widely between studies [11] . In a study from Korea in which 20 SLE patients with PH were included, the 5-year survival rate was 16.8%, while in a study including 28 patients from the United States this figure was 86% [10, 12] . These discrepancies may reflect a different expression of PH according to ethnic, genetic or geographic substrate, although it is more likely they actually reflect differences in the diagnostic approach (mainly echocardiography vs catheterization) as the result of the lack of a standardized and uniform definition of PH [13] .
Right heart catheterization is the only method that definitively establishes a haemodynamic diagnosis of PH because it directly measures PA pressure. However, serious complications related to catheterization are found in $1% of all procedures performed in experienced centres, with occasional fatal events [14] . Moreover, right heart catheterization is an expensive procedure that it is not easily accessible in most health care centres. In contrast, echocardiography is a non-invasive, reproducible, inexpensive and widely available imaging technique useful for estimating PA systolic pressure and other haemodynamic parameters. These characteristics have positioned echocardiography as the most practical modality for the assessment of right heart pressure in patients with suspected PH [1] .
Echocardiographic criteria to detect PH have been developed and are now included in the last updated guidelines for the diagnosis and treatment of PH by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), and endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [1] . Based on a combination of tricuspid regurgitation peak velocity and Doppler-calculated PA systolic pressure at rest, it classifies the presence of PH as unlikely, possible or likely. These criteria attempt to unify different definitions of PH while supporting echocardiography as the initial screening imaging method. Whether these ultrasound-based criteria are useful in patients with SLE remains uncertain because of the lack of longitudinal confirmatory data.
The aim of the present study was to investigate whether a core of echocardiography-based definition for PH, as proposed by the ESC/ERS/ISHLT guidelines, may predict long-term survival in patients with SLE. Demographics, clinical features and several biological markers potentially associated with PH were also assessed.
Material and methods

Study design
The present study is a post hoc analysis from a cohort of patients with SLE that was originally constituted to investigate the behaviour of a variety of acute phase reactants over time [1517] . Patients have been systematically followed every 36 months for >6 years in our outpatient clinic. All procedures have been performed in accordance with the Declaration of Helsinki and local regulations. Protocols for the original cohort and the current study were approved by the local ethics committee, Comisió n de Bioé tica del Instituto Nacional de Cardiología Ignacio Chá vez. At the time of enrolment, all patients signed an informed consent and authorized the use of clinical data and stored sera for further investigations.
From July 2005 to June 2006, 115 adult patients fulfilling the 1997 ACR revised criteria for the classification of SLE were recruited in an outpatient rheumatology clinic [18] . No patient was judged to have clinically apparent infections at the time of recruitment. Pregnant patients and those with malignancy were not included.
On enrolment, all patients were examined by the same physician (L.M.A.-G.) and their medical charts, concomitant laboratory and radiographic reports were studied to assess disease activity and organ damage. Clinical manifestations were defined as follows: arthritis: 52 joints with pain and swelling or effusion confirmed by physical examination; renal involvement: >0.5 g/24 h urine proteins, <50% glomerular filtration rate, >5 white or red blood cells/high-power field of unspun urine, urinary casts or renal failure requiring dialysis; mucocutaneous involvement: malar rash, patchy or diffuse alopecia, oral or nasal ulceration, photosensitivity or discoid rash; neuropsychiatric involvement: seizures, psychosis (not associated with corticosteroids), acute confusional state, lupus migraine, cranial neuropathy, cognitive impairment or transverse myelitis; vasculitis: ulceration, gangrene, periungual infarction or splinter haemorrhages; serositis: pleural or pericardial rubs and effusion, confirmed by chest radiograph or echocardiography, respectively.
All cases diagnosed as interstitial lung disease were confirmed by high-resolution CT, which was interpreted by experienced radiologists, although a specific score for its quantification was not used. Similarly, pulmonary thromboembolism was demonstrated by advanced imaging techniques, including lung CT scans and ventilation/ perfusion lung scintigraphy.
Disease activity was assessed by the SLE Disease Activity Index 2000 (SLEDAI-2K) calculated using a timeframe of 10 days prior to the visit, [19] while the SLICC/ ACR damage index was used to assess cumulative organ damage [20] .
At the same visit, ANA and anti-dsDNA antibodies were detected on HEp-2 cell slides and Crithidia luciliae substrate, respectively (Inova Diagnostics, San Diego, CA, USA). Anti-Ro/SSA, anti-La/SSB, anti-Sm and anti-RNP, as well as antibodies against centromere B and topoisomerase-1 (also called anti-Scl70 antibodies) were measured by ELISA (Inova Diagnostics). aCL and anti-b 2 glycoprotein-1 (anti-b 2 GP1) antibodies also were detected by ELISA (The Binding Site, Birmingham, UK). Lupus anticoagulant was detected according to the guidelines of the International Society on Thrombosis and Haemostasis [21] . High-sensitivity CRP and complement C3 and C4 measurements were performed by nephelometry (IMMAGE Beckman Coulter, Brea, CA, USA). In addition, 5 ml of peripheral blood were obtained and centrifuged (600 g for 15 min at 7 C) and sera were stored in aliquots at À70 C until used.
Categorization of patients according to echocardiography
In our institute, transthoracic studies are performed by certified cardiologists affiliated with the echocardiography training programme and all studies are supervised and reviewed by a cardiologist highly experienced in echocardiography. Echocardiographic data are routinely collected by means of a standardized pro forma file, which includes an evaluation of the thickness and motion of heart walls, motion and areas of valve opening, measurement of cardiac cavities and transvalvular pressure gradients, left ventricle ejection fraction, pulmonary artery pressures and other measurements.
For purposes of the present study, electronic data files from all SLE patients included in our cohort were comprehensively reviewed to identify individuals who underwent transthoracic echocardiography within 3 months before or after their recruitment, for any reason and regardless of the presence of cardiopulmonary symptoms. Patients with a complete echocardiographic study and attending our outpatient clinic on at least one occasion after enrolment were included for the present analysis. 
Serum biomarkers
Stored sera from those patients meeting the inclusion criteria for the present study were unfrozen under standard conditions and the concentration of endothelin-1 (ET-1), monocyte chemotactic protein-1 [MCP-1, also referred as chemokine ligand 2 (CCL2)], IL-17 and IFN-g were measured by quantitative ELISA using commercial kits in accordance with the instructions provided by the manufacturer (R&D Systems, Minneapolis, MN, USA). All assays were performed in duplicate and the mean value was used for calculations.
Statistical analysis
When available, analyses were performed under the principle of trends. Frequencies and proportions were used to describe categorical data and differences were analysed using the 2 test for trends. Continuous variables were expressed as medians [interquartile range (IQR)] and compared using the KruskalWallis test with a Dunn's multiple comparisons post-test. Correlations were assessed using Spearman's rho (r) coefficient with 95% CI. KaplanMeier analyses were used to assess survival, with log rank test for trends to compare the survival curves between groups. The primary outcome was the occurrence of death. The length of survival was defined as the time from entry into the study to either death or loss of follow-up. Lost patients were censored at the time of their last visit. All-cause mortality was used for analyses because the cause of death could not always be confidently ascribed.
All analyses were two-tailed and significance was set at P < 0.05. GraphPad Prism version 4.02 (GraphPad Software, La Jolla, CA, USA) statistical software was used for calculations.
Results
Out of the 115 patients with SLE from the original cohort, 55 satisfied the inclusion criteria for the present study and were analysed. Twenty-six patients were classified as unlikely PH, 16 patients as possible PH and 13 patients as likely PH. Demographics, clinical and imaging data are described in Table 1 . As noted, a history of pulmonary embolism (all events confirmed by advanced imaging studies) was present in 8% of patients unlikely to have PH, 13% in patients with possible PH and 46% of patients with likely PH (P = 0.005). The median SLICC/ACR damage index was 1 (IQR 12) in the unlikely PH group, 3 (24) in the possible PH group and 3 (26; P = 0.0009) in the likely PH group. Similarly, active arthritis was found in 12%, 12% and 38% (P = 0.05), respectively. No differences were observed in other clinical features. Renal function tests, blood cell count and complement C3 and C4 were similar between groups. The frequency of antibodies was also similar between groups (Table 2) .
Regarding serum biomarkers (Fig. 1) , median concentration of ET-1 was 6.2 pg/ml (IQR 4.812) in the unlikely PH group, 4.9 (4.36) in the possible PH group and 5.75 (3.97.5; P = ns) in the likely PH group. Similarly, MCP-1 levels were 310 pg/ml (IQR 166548), 257 (181399.5) and 384 (262634, P = ns), in the unlikely, possible and likely PH groups, respectively. It should be noted that levels of IL-17 and IFN-g were undetectable in almost all serum samples, with no differences between groups, and CRP and ESR were similar between groups (Table 2) .
PA systolic pressure was found to be significantly cor- The most likely cause of PH, as recorded in the medical chart and assigned by the treating physician, was APS in seven cases (54%), six of them having pulmonary www.rheumatology.oxfordjournals.org thromboembolism and the remaining with severe APSassociated cardiac valve disease. Of note, all these patients fulfilled the updated classification criteria for definite APS [22] . Four patients (31%) had SLE-associated interstitial lung disease or recurrent pulmonary haemorrhage. One patient had dilated cardiomyopathy and an additional patient was found to have SLE overlapping SSc.
Survival rate curves are shown in Fig. 2 . First-year survival was 92% in the unlikely PH group, 94% in the possible PH group and 90% in the likely PH group. After 3 years of follow-up, survival was 92%, 89% and 77%, respectively. Finally, 6-year survival was 88%, 87% and 68%, respectively. While there was no difference in the survival rates after 6 years of follow-up between the unlikely and possible PH groups, these were significantly decreased in SLE patients likely to have PH (P < 0.05). Ascribed causes of mortality (recorded in the medical charts) were as follows: in the unlikely PH group, 3/26 (12%) patients died during follow-up because of septic shock, cardiogenic shock and complications of endstage renal disease (1 for each cause). In the possible PH group, 2/16 (13%) patients died because of flares of lupus activity, 1 case with acute glomerulonephritis and the remaining with haemophagocytic syndrome and pulmonary haemorrhage. Finally, 4/13 (31%; P < 0.05 for both comparisons) patients in the likely PH group died, 2 of them because of pulmonary haemorrhage and another 2 because of septic shock (peritonitis and pneumonia). No differences in demographics, clinical or echocardiographic data or laboratory markers were found Data are presented as median (IQR) or n (%). PH: pulmonary hypertension; b 2 GP1: b2 glycoprotein 1; IQR: interquartile range.
www.rheumatology.oxfordjournals.org between SLE patients who died and those who lived, except for the presence of interstitial lung disease, which conferred a risk of death of 5.7 (95% CI 1.2, 27, P = 0.04).
Discussion
The present study demonstrates that the ESC/ERS/ISHLT echocardiography-based definitions for PH may be useful in predicting long-term survival in patients with SLE. Indeed, a PA systolic pressure >50 mmHg in the presence of tricuspid regurgitation velocity >3.4 m/s is associated with >20% increased mortality after 6 years of follow-up. It is well established that echocardiography often overestimates the actual PA pressure measured by right heart catheterization [23] . This may be the case in our study, in which patients with SLE classified as possible PH are similar to those classified as unlikely to have PH in terms of clinical and serological features as well as in overall mortality. In contrast, patients with SLE likely to have PH show a significantly increased mortality after 6 years of follow-up. These patients are also different in terms of accrued chronic organ damage, history of pulmonary thromboembolism and structural cardiac damage as featured by greater right ventricle diameter, left atrium dimension and interventricular septum thickness. These data suggest that SLE patients shown as likely to have PH by echocardiography should be subject to closer monitoring and perhaps more aggressive diagnostic procedures (right heart catheterization) and therapeutic interventions than those unlikely to have PH, while those patients labelled as possible PH seem to represent a mixture of individuals with mild forms of PH and others being misclassified because of the inherent overestimation of echocardiography.
The actual impact of PH on the survival of patients with SLE has not been accurately elucidated, although several case series of long-term followed patients with SLE and PH have shown that 5-year survival ranges from 50 to 87.2% [2426] . This is in agreement with the present study, in which 6-year survival from patients classified as likely to have PH was 68% (overall, 23% increased mortality as compared with SLE patients unlikely to have PH).
Classically, several factors including thrombosis, aPLs, RP and pulmonary vasculitis have been associated with the development of PH in SLE patients as well as with decreased survival [26] . Besides a history of pulmonary thromboembolism (a condition closely associated with both APS and circulating aPLs) and pulmonary vasculitis/haemorrhage, we also found that higher accrued organ damage and long-lasting disease are conditions associated with PH. As previously described, neither overall lupus activity nor neuropsychiatric/renal involvement were found to have prognostic implications for PH-associated mortality [26] .
The exact aetiological relationship between PH and SLE is not yet established, but several intrinsic elements of SLE such as vasculitis, in situ thrombosis and pulmonary fibrosis may induce proliferation of endothelium and vascular smooth muscle as well as damage to the pulmonary vasculature, which ultimately may result in PH [27] . Levels of ET-1 are elevated in patients with either SSc or idiopathic PAH, and this cytokine plays a key role in the induction and maintenance of PH. In this regard, ET-1 inhibitors are highly effective drugs to decrease PA pressure and increase the quality of life and survival in both scleroderma-associated PH and in the primary forms of the disease [28] . The present study was unable to find differences in serum concentration of ET-1 between patients likely and those unlikely to have PH. This lack of association could be explained by the common presence of pulmonary thromboembolism as the cause of PH in our SLE patients. In fact, vascular thrombosis typically does not show large increases in the serum concentration of ET-1, at least in the setting of APS [29] . A previous study performed in SLE found elevated levels of ET-1, but only in patients with RP [30] ; unfortunately, the presence of this clinical manifestation was not systematically collected in our patients. An alternative explanation for this lack of association could rely on TGF-b, a profibrotic cytokine closely involved in the pathogenesis of SSc and idiopathic PH. TGF-b is the main inducer of ET-1 and, in sharp contrast to SSc, circulating levels of TGF-b are low or undetectable in patients with SLE [31] . In agreement with an antithetical role of this cytokine, a number of patients with SSc will develop clinical and serological manifestations suggestive of SLE following therapeutic administration of anti-TGF-b antibodies [31] . Besides ET-1, other soluble molecules are under study as potential biomarkers for PH in SSc and idiopathic PH. For instance, elevated levels of MCP-1 are found in idiopathic PH, while elevated plasma concentrations of IFN-g and decreased IL-17 have been described in patients with SSc [32, 33] . These molecules were not associated with PH in our cohort of patients with SLE. On the basis that inflammatory milieus underlying SLE and SSc are quite different, functioning of diverse biomarkers for PH cannot be extrapolated between diseases and thus the results of the present study may be not entirely unexpected.
FIG. 2 Survival in patients with SLE
KaplanMeier survival plot of patients likely to have PH compared with those with possible or unlikely PH. Overall survival in patients likely to have PH was significantly decreased after 6 years of follow-up (P < 0.05). PH: pulmonary hypertension.
We are aware that our study has limitations, including the lack of right heart catheterization to measure the actual PA pressure and the lack of serial echocardiograms performed at regular intervals. In addition, the selection of patients could be biased by the existence of cardiopulmonary symptoms or signs. Also, the role that therapies introduced after enrolment on the progression and outcome of patients was not assessed in a systematic way. The role of targeted therapies including immunosuppressive and vasodilator drugs on the progression of PH in SLE should be explored through inception cohort studies.
Conclusions
The present study demonstrates that echocardiographybased definitions of PH, as proposed by the ESC/ERS/ ISHLT guidelines, are useful to predict 6-year mortality in patients with SLE.
A history of pulmonary thromboembolism or lung vasculitis/haemorrhage, greater accrued chronic organ damage and long-lasting disease are factors associated with PH in SLE patients.
Rheumatology key message
. Echocardiography-based definitions of pulmonary hypertension by the European Society of Cardiology and the European Respiratory Society and endorsed by the International Society of Heart and Lung Transplantation predict long-term survival in lupus.
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